{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:05:29Z","timestamp":1792004729556,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009399","name":"Macular Disease Foundation Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.oret.2026.04.007","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:21:27Z","timestamp":1776702087000},"page":"833-843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes in Neovascular Age-Related Macular Degeneration with Visit Gaps under Anti-VEGF Therapy in Daily Practice"],"prefix":"10.1016","volume":"10","author":[{"given":"Laura","family":"Goncalves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5431-4991","authenticated-orcid":false,"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0566-6667","authenticated-orcid":false,"given":"Richard","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pollreisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4851-0918","authenticated-orcid":false,"given":"Louise","family":"O\u2019Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-836X","authenticated-orcid":false,"given":"Theodorus Leonardus","family":"Ponsioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8755-0923","authenticated-orcid":false,"given":"Helena Brosa","family":"Morros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-4598","authenticated-orcid":false,"given":"Catherine","family":"Creuzot-Garcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-0274","authenticated-orcid":false,"given":"Mark","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9688-4845","authenticated-orcid":false,"given":"Pierre-Henry","family":"Gabrielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2026.04.007_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2026.04.007_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0039-6257(87)90115-9","article-title":"Pathophysiology of age-related macular degeneration","volume":"31","author":"Young","year":"1987","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.007_bib3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamaophthalmol.2021.1660","article-title":"Defining nonadherence and nonpersistence to anti-vascular endothelial growth factor therapies in neovascular age-related macular degeneration","volume":"139","author":"Okada","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.007_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.oret.2024.01.004","article-title":"European unmet needs in the management of neovascular age-related macular degeneration in daily practice: data from the Fight Retinal Blindness! registry","volume":"8","author":"Boudousq","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.04.007_bib5","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bjophthalmol-2020-317434","article-title":"Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence","volume":"105","author":"Daien","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.007_bib6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12325-019-01147-6","article-title":"Real-world effectiveness and real-world cost-effectiveness of intravitreal aflibercept and intravitreal ranibizumab in neovascular age-related macular degeneration: systematic review and meta-analysis of real-world studies","volume":"37","author":"Carrasco","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.oret.2026.04.007_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2019.10.007","article-title":"Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions","volume":"210","author":"Gillies","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.007_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ophtha.2023.02.021","article-title":"Loss to follow-up in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy in the United States in the IRIS\u00ae registry","volume":"130","author":"Khurana","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.04.007_bib9","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaophthalmol.2018.3578","article-title":"Loss to Follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections","volume":"136","author":"Obeid","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.007_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","article-title":"Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! project","volume":"34","author":"Gillies","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.04.007_bib11","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2026.04.007_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00038-018-1091-9","article-title":"Segmented generalized mixed effect models to evaluate health outcomes","volume":"63","author":"Saeed","year":"2018","journal-title":"Int J Public Health"},{"key":"10.1016\/j.oret.2026.04.007_bib13","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","article-title":"Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration","volume":"122","author":"Arnold","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.04.007_bib14","article-title":"What study designs can be considered for inclusion in an EPOC review and what should they be called?","year":"2017","journal-title":"EPOC Resources for review authors"},{"key":"10.1016\/j.oret.2026.04.007_bib15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.oret.2026.04.007_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"key":"10.1016\/j.oret.2026.04.007_bib17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.oret.2019.05.013","article-title":"Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months","volume":"3","author":"Nguyen","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.04.007_bib18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.04.007_bib19","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00417-025-06798-6","article-title":"Long-term visual outcomes of patients with neovascular age-related macular degeneration treated with anti-VEGF therapy lost to follow-up","volume":"263","author":"Nam","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.007_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1167\/tvst.10.13.5","article-title":"Three-year outcomes of neovascular age-related macular degeneration in eyes that do not develop macular atrophy or subretinal fibrosis","volume":"10","author":"Gabrielle","year":"2021","journal-title":"Trans Vis Sci Tech"},{"key":"10.1016\/j.oret.2026.04.007_bib21","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/IAE.0000000000002779","article-title":"Prevalence and risk factors for the development of physician-graded subretinal fibrosis in eyes treated for neovascular age-related macular degeneration","volume":"40","author":"Teo","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.04.007_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajo.2023.12.011","article-title":"Features associated with vision in eyes with subfoveal fibrosis from neovascular age-related macular degeneration","volume":"261","author":"Teo","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.007_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4274\/tjo.28003","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration","volume":"47","author":"Polat","year":"2017","journal-title":"Turk J Ophthalmol"},{"key":"10.1016\/j.oret.2026.04.007_bib24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41433-022-01957-z","article-title":"Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration","volume":"37","author":"Teo","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2026.04.007_bib25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/IAE.0000000000003368","article-title":"International impact of the covid-19 pandemic lockdown on intravitreal therapy outcomes: fight retinal blindness registry","volume":"42","author":"Zarranz-Ventura","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.04.007_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000529409","article-title":"The effects of treatment regimen on the initial management of macular neovascularization subtypes in age-related macular degeneration","volume":"246","author":"Kodaday","year":"2023","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2026.04.007_bib27","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/IAE.0000000000000173","article-title":"Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration","volume":"34","author":"Vaze","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.04.007_bib28","first-page":"40","article-title":"Unlocking the potential: a comprehensive review of clinical data management strategies and best practices","volume":"84","author":"Aravind Ghosh","year":"2024","journal-title":"Int J Pharm Sci Rev Res"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026001508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026001508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:57:23Z","timestamp":1785743843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653026001508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2468653026001508"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.04.007","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes in Neovascular Age-Related Macular Degeneration with Visit Gaps under Anti-VEGF Therapy in Daily Practice","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}